Clinical trial
Combined Modality Treatment for Patients With Stage IV Melanoma
NCT00313235 · Baylor Research Institute, Other · Completed
Key facts
| NCT number | NCT00313235 |
|---|---|
| Title | Combined Modality Treatment for Patients With Stage IV Melanoma |
| Official title | Combined Modality Treatment for Patients With Stage IV Melanoma: Cyclophosphamide and a Dendritic Cell Vaccine Loaded With Killed Allogeneic Melanoma Cells |
| Lead sponsor | Baylor Research Institute, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma Stage IV |
| Intervention type | Biological |
| Interventions | DC Vaccine and Cyclophosphamide |
| Enrollment | 41 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2012 |
| First posted | Apr 12, 2006 |
| Last update posted | Jun 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: